MORE PERFECT UNION: Tell this Big Pharma CEO: Stop price gouging!

 

For people with type 2 diabetes and obesity-related illnesses, GLP-1 drugs like Ozempic could be a game-changer. But because of pharma greed, these life-saving medications may not be available everywhere. People in the United States pay on average six times what patients do in Germany, Canada, Denmark, or other similar countries for the same exact drug. As President Joe Biden and Senator Bernie Sanders just pointed out in a USA Today op-ed:[1] The simple fact of the matter is that people in Paris, Texas, shouldn’t be paying much higher prices for Ozempic and Wegovy as people in Paris, France. Senator Sanders has called the CEO of Ozempic manufacturer Novo Nordisk to testify on these pricing disparities before the Senate Health, Education, Labor, and Pensions Committee this September. Ahead of that hearing, send a message directly to Big Pharma CEO Lars Jørgensen and demand that he lower prices on Ozempic and Wegovy! SIGN AND SEND Though the weight-loss benefits of GLP-1 drugs get the headlines, the benefits for people with diabetes are even greater. More than 10 percent of Americans have type 2 diabetes. Nearly one-fifth of people on Medicaid have a condition that could be treated with Ozempic or Wegovy, and surging demand combined with Novo Nordisk’s greed are swallowing state Medicaid budgets. For the first nine months of 2023, Novo Nordisk posted a profit of over $9 billion, an increase of almost 50 percent from 2022. The company attributes most of the growth to U.S. sales.[2] And while Novo Nordisk pays less than $5 per dose, it charges Americans $1,100! We must send a message to Big Pharma: Stop price-gouging American consumers! Send your message to Novo Nordisk CEO Lars Jørgensen today! In solidarity, -Faiz Faiz Shakir, Co-Founder More Perfect Union SUPPORT OUR WORK

PAID FOR BY MORE PERFECT UNION